Die Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Die Wu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Sen He
National Anti‐Doping Laboratory Beijing Sport University Beijing China
1 shared publicationTiantian Yan
Shanghai Anti‐doping Laboratory Shanghai University of Sport Shanghai China
1 shared publicationXiao Liu
Shanghai Anti‐doping Laboratory Shanghai University of Sport Shanghai China
1 shared publication- Xiao Liu
Shanghai Anti‐doping Laboratory of Shanghai University of Sport Shanghai China
1 shared publication Xiaoci Zheng
Shanghai Anti‐doping Laboratory Shanghai University of Sport Shanghai China
1 shared publication- Xiaoci Zheng
Shanghai Anti‐doping Laboratory of Shanghai University of Sport Shanghai China
1 shared publication
Latest Publications
- 25 June 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (9) , 1203-1211
Comparison of RNA Extraction Method for Human Whole Blood: Assessing the Quality, Quantity, and Impact of RBC Lysis Across TRIzol, Invitrogen, and Qiagen Systems
Whole‐blood samples are widely utilized in the field of doping control. Owing to the limited volume of whole blood collected from athletes and the fact that Tempus Blood RNA Tube and Paxgene Blood RNA Tube are primarily intended for RNA stabilization and require dedicated extraction workflows, this study aimed to develop a more efficient and cost‐effective RNA extraction approach using smaller volumes of EDTA‐anticoagulated whole blood. RNA was extracted from human whole blood using three different methods: the TRIzol Reagent, the PureLink RNA Mini Kit (Invitrogen), and the QIAamp RNA Blood Mini Kit (Qiagen). Apparent RNA yield and purity were assessed via a NanoDrop spectrophotometer, and RNA suitability for RT‐qPCR analysis was evaluated. The results indicate that red blood cell lysis influenced RNA extraction outcomes. Additionally, clear differences in RNA quality and quantity were observed. Among the three methods evaluated, the QIAamp RNA Blood Mini Kit (Qiagen) tended to yield higher apparent RNA concentrations, purity, and integrity. Therefore, under the exploratory conditions tested, the QIAamp RNA Blood Mini Kit (Qiagen) demonstrated comparatively favorable performance for RNA‐based biomarker analysis relevant to doping control.
- 25 June 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (9) , 1203-1211
Comparison of RNA Extraction Method for Human Whole Blood: Assessing the Quality, Quantity, and Impact of RBC Lysis Across TRIzol, Invitrogen, and Qiagen Systems
Whole‐blood samples are widely utilized in the field of doping control. Owing to the limited volume of whole blood collected from athletes and the fact that Tempus Blood RNA Tube and Paxgene Blood RNA Tube are primarily intended for RNA stabilization and require dedicated extraction workflows, this study aimed to develop a more efficient and cost‐effective RNA extraction approach using smaller volumes of EDTA‐anticoagulated whole blood. RNA was extracted from human whole blood using three different methods: the TRIzol Reagent, the PureLink RNA Mini Kit (Invitrogen), and the QIAamp RNA Blood Mini Kit (Qiagen). Apparent RNA yield and purity were assessed via a NanoDrop spectrophotometer, and RNA suitability for RT‐qPCR analysis was evaluated. The results indicate that red blood cell lysis influenced RNA extraction outcomes. Additionally, clear differences in RNA quality and quantity were observed. Among the three methods evaluated, the QIAamp RNA Blood Mini Kit (Qiagen) tended to yield higher apparent RNA concentrations, purity, and integrity. Therefore, under the exploratory conditions tested, the QIAamp RNA Blood Mini Kit (Qiagen) demonstrated comparatively favorable performance for RNA‐based biomarker analysis relevant to doping control.
- 20 February 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (9) , 1675-1680
RNA‐Based Biomarkers of Iron Metabolism in Dried Blood Spots for Detecting Recombinant Human Erythropoietin in Doping Control
Erythropoietin (EPO) abuse in sports has been a major challenge in doping analysis for decades. Although the Athlete Biological Passport (ABP) serves as an indirect method for EPO detection, it requires continual improvement to increase its sensitivity and reliability. Biomarkers related to iron metabolism and erythropoiesis as complementary parameters to enhance the ABP hematology module have the potential to improve its ability to detect EPO indirectly. In this study, RNA was extracted from dried blood spot (DBS) samples collected over 28 days (days 0, 1, 3, 5, 7, 9, 11, 13, 21, and 28) following the administration of therapeutic doses of recombinant human EPO (Yibiao, 50 IU/kg per dose, administered subcutaneously twice). The expression of four genes, namely, mitoferrin 1 (MFRN1), ferrochelatase (FECH), ferroportin (FPN), and ferritin heavy chain (FTH), was analyzed. The results revealed significant expression changes, with MFRN1 demonstrating peak increases of 2.43‐fold, and presented detection windows extending beyond Day 9, providing greater sensitivity and longer detection windows than traditional ABP parameters do. The integration of MFRN1 into the ABP framework has the potential to increase the detection of EPO misuse in athletes.
- 20 February 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 17 (9) , 1675-1680
RNA‐Based Biomarkers of Iron Metabolism in Dried Blood Spots for Detecting Recombinant Human Erythropoietin in Doping Control
Erythropoietin (EPO) abuse in sports has been a major challenge in doping analysis for decades. Although the Athlete Biological Passport (ABP) serves as an indirect method for EPO detection, it requires continual improvement to increase its sensitivity and reliability. Biomarkers related to iron metabolism and erythropoiesis as complementary parameters to enhance the ABP hematology module have the potential to improve its ability to detect EPO indirectly. In this study, RNA was extracted from dried blood spot (DBS) samples collected over 28 days (days 0, 1, 3, 5, 7, 9, 11, 13, 21, and 28) following the administration of therapeutic doses of recombinant human EPO (Yibiao, 50 IU/kg per dose, administered subcutaneously twice). The expression of four genes, namely, mitoferrin 1 (MFRN1), ferrochelatase (FECH), ferroportin (FPN), and ferritin heavy chain (FTH), was analyzed. The results revealed significant expression changes, with MFRN1 demonstrating peak increases of 2.43‐fold, and presented detection windows extending beyond Day 9, providing greater sensitivity and longer detection windows than traditional ABP parameters do. The integration of MFRN1 into the ABP framework has the potential to increase the detection of EPO misuse in athletes.
- 27 May 2022
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (11-12) , 1974-1983
Detection of de‐N‐glycosylated EPO with SDS‐PAGE: A complementary confirmation procedure for recombinant EPO in blood samples
Frameshift variant c.577del in the EPO gene can result in the extension of the amino acid sequence of EPO by invalidating the termination codon. As the molecular weight of its encoded protein EPO (VAR‐EPO) is similar to that of rEPO, the World Anti‐Doping Agency has published Annex B to the TD2022EPO in order to protect athletes with variant c.577del from the suspicion of rEPO administrations. However, it is still necessary to develop a confirmation method for rEPO that can discriminate rEPO from VAR‐EPO.Based on the glycosylated characteristic of EPO, we selected the detection of de‐N‐glycosylated EPO as a complementary confirmation method for rEPO in blood samples. All samples were analyzed for both intact EPO and de‐N‐glycosylated EPO with SDS‐PAGE, including rEPO spiked samples and blank samples.The results showed that, after de‐N‐glycosylation, a single‐band was detected in samples collected from non‐variant carriers, no matter whether the sample was spiked with rEPO. In samples collected from variant carriers, a double‐band was detected. The ratio of lower band to upper band increased significantly corresponding to the concentration of rEPO. We calculated a series of cut‐off values by normality distribution function to identify the presence of rEPO. Neither false positive results in blank samples nor false negative results in spiked samples at the applicable Minimum Required Performance Levels were found. This indicates that this method could be adopted as a complementary confirmation method for rEPO in blood samples. A revised testing strategy was also proposed, which would discriminate rEPO directly without further investigation.
- 27 May 2022
- Published by Wiley in Drug Testing and Analysis
- Vol. 14 (11-12) , 1974-1983
Detection of de‐N‐glycosylated EPO with SDS‐PAGE: A complementary confirmation procedure for recombinant EPO in blood samples
Frameshift variant c.577del in the EPO gene can result in the extension of the amino acid sequence of EPO by invalidating the termination codon. As the molecular weight of its encoded protein EPO (VAR‐EPO) is similar to that of rEPO, the World Anti‐Doping Agency has published Annex B to the TD2022EPO in order to protect athletes with variant c.577del from the suspicion of rEPO administrations. However, it is still necessary to develop a confirmation method for rEPO that can discriminate rEPO from VAR‐EPO.Based on the glycosylated characteristic of EPO, we selected the detection of de‐N‐glycosylated EPO as a complementary confirmation method for rEPO in blood samples. All samples were analyzed for both intact EPO and de‐N‐glycosylated EPO with SDS‐PAGE, including rEPO spiked samples and blank samples.The results showed that, after de‐N‐glycosylation, a single‐band was detected in samples collected from non‐variant carriers, no matter whether the sample was spiked with rEPO. In samples collected from variant carriers, a double‐band was detected. The ratio of lower band to upper band increased significantly corresponding to the concentration of rEPO. We calculated a series of cut‐off values by normality distribution function to identify the presence of rEPO. Neither false positive results in blank samples nor false negative results in spiked samples at the applicable Minimum Required Performance Levels were found. This indicates that this method could be adopted as a complementary confirmation method for rEPO in blood samples. A revised testing strategy was also proposed, which would discriminate rEPO directly without further investigation.